S A M V A T 2083

Wednesday, 04 November 2026

SSL Research Centre
www.stockholdingservices.com



Diwali Stock Picks 2026

Sl. No	Company Name	NSE Symbol	Industry	Market Cap (₹ in Crs)	CMP (₹) as on 04th Nov 2026	Target (₹)	Upside Potential (%)
1	Aeroflex Industries Limited	AEROFLEX	Industrial Products	6,783.28	512.60	612	19.39%
2	Azad Engineering Limited	AZAD	Electrical Equipment	16,540.03	2,561.10	2,969	15.93%
3	Mankind Pharma Limited	MANKIND	Pharma	1,02,228.66	2,475.00	2,991	20.85%
4	Netweb Technologies India Limited	NETWEB	IT - Services	24,300.97	4,087.80	4,647	13.68%
5	Navin Fluorine International Limited	NAVINFLUOR	Chemicals & Petrochemicals	43,752.40	8,530.00	9,931	16.42%
6	DCB Bank Limited	DCCBANK	Banks	5,954.38	184.81	240	29.86%
7	Lumax Auto Technologies Limited	LUMAXTECH	Auto Components	13,956.65	2,047.70	2,293	11.98%
8	Leela Palaces Hotels & Resorts Ltd	THELEELA	Leisure Services	21,802.44	652.85	735	12.58%

Equity Market Observations: The National Index Nifty 50 declined 10.88% from Diwali 2025 to October 30, 2026, amid geopolitical tensions, elevated crude oil prices, tariff measures, sustained FII outflows, rupee depreciation and valuation compression. Real GDP expanded 7.8% YoY in Q1FY27, while the RBI projects FY27 GDP growth of 7.1%, supported by domestic consumption, infrastructure investment and manufacturing activity. Industrial production grew 6.7% YoY in September 2026, while CPI inflation stood at 5.54% and the repo rate at 5.50%. Despite these headwinds, India's underlying economic fundamentals continue to demonstrate resilience. The above recommended Diwali Stock Picks 2026 comprise eight handpicked companies across defence, AI-led infrastructure, specialty chemicals, pharmaceuticals, banking, hospitality and automotive components. The stocks have been selected based on historical financial performance, reasonable valuations, earnings visibility, management guidance and company-specific growth opportunities. Their strategic positioning, capacity expansion initiatives and long-term business prospects offer potential for sustained earnings growth. ***We believe the Indian equity markets are likely to remain constructive and poised to reclaim its previous all-time high (26341.20) by upcoming Diwali 2027 on strength of corporate earnings***. *The correction during Samvat 2082 presents an opportunity to accumulate quality businesses at attractive valuations*. ***With a recommended investment horizon of 8–12 months, the Diwali Stock Picks 2026 aim to capture potential market recovery and company-specific growth opportunities as we enter Samvat 2083, while maintaining a focus on prudent diversification, disciplined investing and long-term value as well as wealth creation.***

1. Aeroflex Industries Limited

Cmp: ₹ 512.60 **Tgt: ₹ 612** **Upside Potential: 19.39%**

Aeroflex Industries is a leading global manufacturer of high-precision flexible flow solutions for the safe and efficient transfer of solids, liquids and gases across diverse industrial applications. With 28 years of industry experience and a presence in over 90 countries, the company serves key sectors, including data centres, marine, aerospace, oil & gas, chemicals, semiconductors and renewable energy. Leveraging advanced engineering and specialised manufacturing capabilities, Aeroflex focuses on innovation and value-added solutions, with 16 products under R&D for data centre applications, strengthening its positioning in emerging high-growth industries.


Investment Rationale:

- **Strong earnings growth and improving profitability:** Record Q2FY27 revenue of ₹207.68 crore, with EBITDA growth of 24% YoY and margins expanding 393 bps to 24.27%. Core metal flexible hoses and value-added assemblies recorded H1FY27 revenue growth of 40% and 44%, respectively.
- **Liquid cooling solutions as a key growth driver:** Liquid cooling contributed 24% of H1FY27 revenue, supported by rising AI-led data centre investments. Management upgraded its FY27 skid assembly revenue target to ₹150–200 crore, international supplies offer additional growth potential.
- **Capacity expansion to strengthen revenue visibility:** The company plans ₹202 crore of capex to increase hose capacity by 50% to 30 million metres and double skid assembly capacity to 30,000 units annually by March 2028 which may offers incremental annual revenue potential of ₹500–550 crore.
- **Strong revenue guidance and healthy margin outlook:** Management expects ~ 60% revenue growth in FY27, targeting ₹715–725 crore, supported by growing demand across data centres, firefighting and industrial applications. EBITDA margins to remain around 25%, with the ₹1,500 crore FY30 revenue ambition.
- **Product innovation and operational efficiencies to support growth**: Focus on high-precision engineered solutions, complementary liquid cooling products and manufacturing automation to strengthen its value-added portfolio. Potential cost efficiencies from the Hyd-Air merger could further support operational performance.

Valuation: *We expect the company to deliver a strong CAGR of 49% and 72% in revenues and PAT, respectively over FY26-FY28E. The company is trading at a valuation equal to its 1 year median PE. Driven by its strong growth outlook and financial performance, we value the company at 62x PE and arrive at a price of Rs. 612 with an upside potential of 19.39%.*

Key Data	
BSE Code	543972
NSE Code	AEROFLEX
Bloomberg Code	AEROFLEX:IN
Basic Industry	Iron & Steel Products
Market Cap(Cr.)	6,783.28
No. of Shares(Cr.)	13.24
Face Value	2
52 Week High/Low	613.70/158

Shareholding Pattern



2. Azad Engineering Limited

Cmp: ₹ 2561.10 **Tgt: ₹ 2969** **Upside Potential: 15.93%**

Azad Engineering Limited is a leading manufacturer of highly engineered, mission- and life-critical components for the Energy & Oil and Gas and Aerospace & Defence sectors. The company serves customers across 11+ countries, including global OEMs such as GE Vernova, Mitsubishi Heavy Industries, Siemens Energy, Baker Hughes, Rolls-Royce, Boeing and Pratt & Whitney Canada. With a portfolio of over 1,700 qualified components and 45+ manufacturing processes, Azad is also among the few qualified manufacturers of nuclear turbine airfoils in India.


Investment Rationale:

- **Strong earnings growth and healthy operating margins:** Azad Engineering reported Q1FY27 revenue growth of 26.8% YoY to ₹170.5 crore, while EBITDA increased 32.1% to ₹64 crore, with margins expanding 150 bps to 37.6%. Strong demand across energy and aerospace segments, supports sustained earnings growth.
- **Capex to accelerate order book execution:** The commissioning of dedicated manufacturing facilities for GE Vernova, Baker Hughes and other global OEMs is expected to accelerate revenue conversion from the company's order book exceeding ₹6,500 crore. Recently secured Rs 53 crores order from BHEL to manufacture and supply critical gas turbine components.
- **Gas turbine demand and strategic OEM partnerships to drive growth:** Rising global investments in gas turbines and energy security are strengthening demand for precision-engineered components. Long-term contracts, and expansion into high-value hot-section components, provide strong revenue visibility and opportunities to increase customer wallet share.
- **Indigenous turbojet engine development opens new growth opportunities:** Azad's successful delivery of India's first indigenous expendable turbojet engine to GTRE/DRDO marks its entry into integrated propulsion systems.
- **Operating leverage and working capital improvement to support profitability:** Management expects EBITDA margins of 32–35% over the long term, supported by higher capacity utilisation, localisation and operational efficiencies. Its target to reduce working capital days to 160–180 by H2FY27 could improve cash flow generation as newly commissioned facilities scale up.

Valuation: *Company's transition into engine manufacturing, strong operating margins and improving return on equity as capacity utilisation ramps up, provides a robust outlook. We assign 67x EV multiple to the company with an upside of 15.93% with a target of Rs 2969.*

Key Data	
BSE Code	544061
NSE Code	AZAD
Bloomberg Code	AZAD:IN
Basic Industry	Heavy Electrical Equipment
Market Cap(Cr.)	16,540.03
No. of Shares(Cr.)	6.46
Face Value	2
52 Week High/Low	3127.90/1360

Shareholding Pattern



3. Mankind Pharma Limited

Cmp: ₹ 2475 **Tgt: ₹ 2991** **Upside Potential: 20.85%**

Mankind Pharma is India's 4th-largest pharmaceutical company by value and 2nd-largest by volume in the Indian Pharmaceutical Market (IPM). The company has a strong domestic presence across acute and chronic therapies, including anti-infectives, cardiovascular, anti-diabetic, gastrointestinal, respiratory and gynaecology, alongside consumer healthcare and specialty products. With 32 manufacturing facilities, over 1,000 products and a presence in more than 70 countries, Mankind focuses on affordable healthcare while expanding its chronic therapy portfolio and international specialty business.


Investment Rationale:

- **Strong earnings growth and margin expansion:** Mankind Pharma reported robust Q2FY27 performance, with revenue growing 17.3% YoY, EBITDA up 27.2% to ₹1,175 crore, and PAT up 37.7% to ₹716 crore. EBITDA margin expanded, driven by improved gross margins and operating leverage.
- **Domestic growth driven by volume recovery and chronic portfolio:** Domestic revenue grew 14.8% YoY, outperforming the IPM. Improving volume growth, rising chronic portfolio contribution and strong traction in cardiac and anti-diabetes therapies support sustained growth, management targets 1.1–1.2x IPM outperformance over the next two quarters.
- **Strong international growth and geographical diversification:** International revenue surged 33% YoY, supported by BSV International (+34%), Mankind US (+29%) and other markets (+37%). Expanding specialty products and geographical diversification, alongside management's double-digit FY27 international growth guidance, provide additional revenue visibility.
- **Consumer healthcare recovery to support incremental growth:** Consumer healthcare revenue remained subdued amid weak category demand. Modern trade and e-commerce grew 55%. Management expects high-single-digit growth in FY27, with a potential recovery to double-digit growth in FY28.
- **Healthy profitability outlook and improving balance sheet:** Management maintained FY27 EBITDA margin guidance of 25.5–26.5%, supported by operating efficiencies and a favourable product mix. Net debt declined with acquisition-related debt expected to be repaid by FY28.

Valuation: *The company is trading at discount to its 1year and 3 year median PE. We value the company at 45x PE and expect revenue/EBITDA/PAT growth of 17.6%/19.0%/20.2% over FY26-FY28E. We recommend a BUY call with a target of Rs. 2991, upside potential of 20.85%.*

Key Data	
BSE Code	543904
NSE Code	MANKIND
Bloomberg Code	MANKIND IN
Basic Industry	Pharmaceuticals
Market Cap(Cr.)	1,02,228.66
No. of Shares(Cr.)	41.30
Face Value	1
52 Week High/Low	2,642/1,909.70

Shareholding Pattern



4. Netweb Technologies India Limited

Cmp: ₹ 4087.80 **Tgt: ₹ 4647** **Upside Potential: 13.68%**

Netweb Technologies India Limited is a leading Indian manufacturer of high-end computing solutions, offering supercomputing, AI systems, private cloud infrastructure and data centre servers. The company has deployed over 600 supercomputing systems and 10,000 GPU-based AI systems, with its supercomputers featuring 17 times in the global Top 500 rankings. Backed by partnerships with NVIDIA, AMD and Intel, its strong market presence and order book of ₹2,629 crore support future growth.


Investment Rationale:

- **Record Financial Performance & Profitability:** Q2FY27 revenue surged 335.7% YoY to ₹1,323 crores, while operating EBITDA rose 334% to ₹197 crores with a margin of 14.9%. PAT increased 334.8% to ₹137 crores, supported by strong execution and growing demand for AI infrastructure.
- **Robust Order Book & Revenue Visibility:** The company reported a confirmed order book of ₹2,629 crores, additional L1 orders of ₹653 crores and an active business pipeline of ₹11,152 crores as of September 2026. Management indicated approximately 60% pipeline conversion and standard order execution timelines of 10–16 weeks, supporting future revenue visibility.
- **AI-Led Growth & Strong Revenue Guidance:** AI systems contributed 58.4% of Q2FY27 revenue, registering 1,068% YoY growth. Management targets approximately ₹4,000 crores revenue in FY27 and remains confident of sustaining 30–40% annual growth over the next few years, driven by expanding AI, HPC and private cloud demand.
- **Technology Expansion & Strong Financial Position:** Netweb raised ₹1,200 crores through a QIP, strengthening its working capital position and maintaining net cash of approximately ₹14 crores.
- **Favourable Industry Outlook & Government Initiatives:** India's ₹10,300 crores IndiaAI Mission and expanding GPU infrastructure are accelerating demand for indigenous computing solutions. Growing investments in sovereign AI, data centres and the National Supercomputing Mission 2.0 offer significant long-term opportunities for Netweb's high-performance computing portfolio.

Valuation: *The stock is currently trading at a P/E of 64.57x, with an EPS of ₹63.31, compared to the industry P/E/PEG of 22.7x/1.04x and its 5-year average P/E of 150.9x, indicating a discounted valuation. We assign a P/E multiple of 65.0x, deriving a target price of ₹4,647, implying an upside potential of 13.68% from the current market price as of November 3, 2026.*

Key Data	
BSE Code	543945
NSE Code	NETWEB
Bloomberg Code	NETWEB:IN
Industry	IT - Services
Market Cap(Cr.)	24,027.51
No. of Shares(Cr.)	5.94
Face Value	2.00
52 Week High/Low	5,813 / 2,920

Shareholding Pattern



5. Navin Flourine International Limited Cmp: ₹ 8530 Tgt: ₹ 9931 Upside Potential: 16.42%

Navin Fluorine International Limited is one of India's leading specialty fluorochemical manufacturers, with integrated manufacturing facilities in India and the UK. The company operates across three key segments—High Performance Products (HPP), Specialty Chemicals and CDMO, offering over 74 products, including refrigerant gases under the MAFRON brand, inorganic fluorides and specialty fluorides. It has a strong presence across domestic and international markets, including North America, Europe, the Middle East and Asia-Pacific.


Investment Rationale:

- **Strong earnings growth and margin expansion:** Q2FY27 revenue surged 57% YoY, while EBITDA grew 66%, with margins expanding to 34.2%. PAT increased 81% to ₹269 crore, reflecting strong operating leverage and an improving product mix, supporting sustained earnings momentum.
- **Long-term HFO contract strengthens revenue visibility**: The four-year extension of the Solstice HFO supply agreement until December 2032 adds approximately US$180 million in potential revenue. Higher contracted volumes, firm HFC pricing and the ramp-up of the new HF plant are expected to support near-term growth and improve revenue visibility.
- **Specialty chemicals capacity expansion to accelerate growth:** The specialty chemicals business reached a quarterly revenue run rate of ₹350 crore, backed by healthy order visibility. The recently commissioned MPP debottlenecking, ongoing Nectar ramp-up and upcoming Chemos are expected to drive incremental revenue growth over the next 12 months.
- **CDMO business to benefit from capacity additions and strong demand:** Management remains on track to achieve its US$100 million FY27 CDMO revenue target. The commissioning of CGMP4 Phase 2 by Q4FY27, is expected to strengthen growth visibility, with combined Phase 1 and 2 facilities offering peak annual revenue potential of ₹900–1,000 crore by FY28–29.
- **Healthy margin outlook and strategic capacity investments**: Management expects FY27 EBITDA margins to remain near H1 levels, supported by a favourable business mix. Planned FY27 capex of approximately ₹700 crore, is expected to support the company's high-value product portfolio and medium-term earnings growth.

Valuation: *The company is currently trading at a discount to its 1-year, 3-year and 5-year historical average P/E multiples. We value the stock at 46x P/E, arriving at a target price of Rs. 9931 and recommend a BUY with a potential upside of 16.42%.*

Key Data	
BSE Code	532504
NSE Code	NAVINFLOUR
Bloomberg Code	NFIL IN
Basic Industry	Specialty Chemicals
Market Cap(Cr.)	43,752.40
No. of Shares(Cr.)	5.13
Face Value	2
52 Week High/Low	8949.50/5440.00

Shareholding Pattern



6. DCB Bank Limited

Cmp: ₹ 184.81 **Tgt: ₹ 240** **Upside Potential: 29.86%**

DCB Bank is a new-generation private sector bank with a pan-India network of 483 branches and over 3.2 million active customers as of 30th September 2026. The bank's total business surpassed ₹1,40,000 crore, supported by a granular and diversified loan and deposit franchise. Total advances grew 21.05% YoY to ₹64,127 crore, while deposits increased 18.62% YoY to ₹76,839 crore. The bank maintains a healthy capital position with a Capital to Risk-Weighted Assets Ratio (CRAR) of 16.63%. Its diversified business portfolio spans retail, micro-SME, SME, mid-corporate, agriculture, government, public sector entities, banks, co-operative banks and NBFCs, providing a broad-based foundation for sustainable growth.


Investment Rationale:

- **Record Earnings & Profitability:** DCB Bank reported its highest-ever quarterly PAT of ₹236 crore, up 29% YoY, supported by 17% NII growth. RoA and RoE improved to 1.03% and 14.6%, respectively.
- **Robust Business Growth:** Advances grew 21% YoY to ₹64,127 crore, while deposits increased 19% to ₹76,839 crore. Management expects 18–20% loan growth, driven by mortgages, gold loans and corporate lending.
- **Improving Margins & Efficiency:** Cost-to-income ratio declined to an 18-quarter low of 59.64%. Management expects NIM improvement in H2FY27 through lower funding costs, loan repricing and liquidity deployment.
- **Strong Asset Quality:** GNPA/NNPA improved to 2.29%/0.73%, reaching 23-quarter lows, while credit cost remained low at 0.28% and PCR strengthened to 81.38%.
- **Long-Term Growth Outlook:** Higher branch productivity, diversified lending, improving operating efficiency and the proposed capital raise are expected to support sustainable business growth.
- **Key Risks:** Deposit competition, NIM pressure, gold loan concentration, regulatory changes, potential credit stress and dilution from the proposed capital raise.

Valuation: DCB Bank delivered a strong Q2FY27 performance, with RoA/RoE at 1.0%/13.8%, respectively. Advances grew 21.1% YoY, driven by healthy growth in gold loans, corporate and agricultural lending, while the CASA ratio improved 65 bps QoQ. Core operating profit increased 26.2% YoY, supported by robust fee income and controlled operating expenses, offsetting NIM compression. Asset quality remained stable, with net slippages contained at 7 bps. Management expects business growth of 18–20% in FY27E, supporting a positive earnings outlook. *Considering these factors, we maintain our BUY rating with a 12-month target price of ₹240, valuing the bank at 1.0x FY28E adjusted book value (P/ABV).*

Key Data	
BSE Code	532772
NSE Code	DCBBANK
Bloomberg Code	DCBBANK:IN
Industry	Banks
Market Cap(Cr.)	4731.136
No. of Shares(Cr.)	25.6
Face Value	10
52 Week High/Low	234.80/156.55

Shareholding Pattern



7. Lumax Auto Technologies Limited

Cmp: ₹ 2047.70 **Tgt: ₹ 2293** **Upside Potential: 11.98%**

Lumax Auto Technologies Limited (LATL) is a leading Indian automotive component manufacturer, commanding over 65% market share in gear shifters across passenger vehicle customers. The company offers a diversified portfolio spanning interior systems, mechatronics, electronics, control systems and alternative-fuel components. LATL caters to leading OEMs, including Maruti Suzuki, Mahindra & Mahindra and Tata Motors. Its established market position, diversified product portfolio and robust order book of ₹1,879 crore provide strong visibility for sustained growth.


Investment Rationale:

- **Robust Financial Performance:** Revenue increased 35% YoY to ₹1,556 crores in Q2FY27, while PAT surged 58% YoY. H1FY27 EBITDA grew 42% YoY, with margins improving 90 bps, reflecting healthy operating performance.
- **Strong Order Book & Growth Visibility:** The order book increased to ₹1,879 crores in Q2FY27 from ₹1,600 crores in Q1FY27. Management reiterated its ambition to achieve approximately 20% revenue CAGR through FY31, targeting revenue of over ₹11,000 crores, supported by organic expansion and potential acquisitions.
- **Mechatronics Expansion & New Product Launches:** Mechatronics is expected to emerge as the fastest-growing vertical, targeting ₹800–1,000 crores revenue by FY31.The Body Control Module (BCM) commenced production in July 2026, backed by a ₹250 crores order book, while the company plans to expand its product categories to ten by FY31.
- **Margin Expansion & Operational Efficiency:** Management expects to sustain current profitability despite near-term raw material inflation, supported by cost pass-through arrangements with OEMs. Operational efficiencies, product diversification and scale benefits are expected to support its medium-term ambition of improving EBITDA margins by 100–200 bps towards 17–18%.
- **Favourable Industry Outlook & Strategic Growth:** India's automotive industry recorded 10.4% sales growth in FY26, supported by domestic demand and policy initiatives. LATL's expanding CNG component business, localisation initiatives and increasing adoption of advanced automotive technologies position it to capture opportunities across conventional and alternative-fuel vehicles.

Valuation: *The stock is currently trading at a P/E of 38.43x, with an EPS of ₹53.22, compared to the industry P/E/PEG of 27.80x/0.85x and its 3-year average P/E of 30.2x, indicating a premium valuation. We assign a P/E multiple of 30.4x, deriving a target price of ₹2,293, implying an upside potential of 12 % from the current market price as of November 3, 2026.*

Key Data	
BSE Code	532796
NSE Code	LUMAXTECH
Bloomberg Code	LMAX:IN
Industry	Auto Components
Market Cap(Cr.)	13,883.72
No. of Shares(Cr.)	6.82
Face Value	2.00
52 Week High/Low	2,190 / 1,129

Shareholding Pattern



8. Leela Palaces Hotels & Resorts Limited

Cmp: ₹ 652.85 Tgt: ₹ 735 Upside Potential: 12.58%


The Leela Palaces, Hotels and Resorts is one of India's leading luxury hospitality brands, renowned for its premium hotels, resorts and iconic properties across major business and leisure destinations. The company operates through a combination of owned and managed properties, with a portfolio of 15 operational properties and 10 upcoming properties in its development pipeline. By FY30, its portfolio is expected to reach 5,257 keys, comprising 2,646 owned and 2,611 managed keys. Leela's operational portfolio accounts for approximately 12% of India's luxury hospitality room inventory. Its strong brand positioning, premium pricing power, expanding asset-light portfolio and improving financial position, with net debt-to-EBITDA at 1.4x, provide a strong foundation for sustainable long-term growth.

Investment Rationale:

- **Strong Earnings & Operating Performance:** Leela reported robust Q2FY27 performance, with operating revenue growing 33% YoY and EBITDA rising 36%, supported by a 30% increase in RevPAR and strong demand across luxury hospitality segments. **Strong Pricing Power & Occupancy:** Average Daily Rate (ADR) increased 30% YoY to ₹25,046, while occupancy stood at 69%. Premium positioning, improving suite occupancy and strong corporate and leisure demand supported revenue growth. **Improving Margins & Operating Efficiency:** EBITDA margin expanded 118 bps YoY to 46%, driven by operating leverage and cost efficiencies. Management fee income surged 76% YoY, supporting higher-margin, asset-light growth. **Robust Expansion Pipeline:** The company has contracted over 5,200 keys by FY30, with approximately 50% under the asset-light model. Upcoming properties and luxury residences are expected to strengthen its domestic and international presence. **Strengthening Balance Sheet & Growth Outlook:** Net debt-to-EBITDA improved to 1.4x, while finance costs declined 37% in H1FY27. **Key Risks:** High capital expenditure requirements, delays in project execution and regulatory approvals, slower ramp-up of new properties, continued Dubai JV losses and potential weakness in luxury travel demand could impact profitability. **Valuation:** *THELEELA delivered a robust Q2FY27 operational performance, with RevPAR rising 30% YoY to ₹17,225, driven by a 30% increase in ARR to ₹25,046, supported by strong luxury demand, the BRICS Summit and a shift towards premium room categories. City hotels remained the key growth driver, reporting 26% YoY RevPAR growth to ₹15,948 in H1FY27, with occupancy improving to 74%, while resorts recorded 18% RevPAR growth to ₹14,722. We remain positive on the company's H2FY27 outlook, supported by sustained premium pricing, strong seasonal demand and improving occupancy. Considering its superior pricing power, strong brand positioning and healthy growth prospects, we maintain our BUY rating with a target price of ₹735 per share, valuing the company at 22.5x FY28E adjusted EV/EBITDA.*

Key Data	
BSE Code	544408
NSE Code	THELEELA
Bloomberg Code	THELEELA:IN
Industry	Leisure Services
Market Cap(Cr.)	21805.19
No. of Shares(Cr.)	33.4
Face Value	10
52 Week High/Low	682.75/381.05

Shareholding Pattern



StockHolding Services Limited
(Formerly known as SHCIL Services Limited)
CIN NO: U65990MH1995GOI085602 SEBI - RA: INH000001121
Plot No. P-51, T.T.C. Industrial Area, MIDC Mahape, Navi Mumbai – 400 710
Call to us: 91-080-69850100 E_Mail: customerdesk@stockholdingservices.com www.stockholdingservices.com

Disclaimer

The research recommendations and information are solely for the personal information of the authorized recipient and does not construe to be an offer document or any investment, legal or taxation advice or solicitation of any action based upon it.

The research services ("Report") provided is for the personal information of the authorized recipient(s) and is not for public distribution. The report is based on the facts, figures and information gathered from reliable sources that are considered true, correct and reliable. The report is provided for information of clients only and does not construe to be an investment advice. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as a confirmation of any transaction. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report and should consult its own advisors to determine the merits and risks of such an investment. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. SSL is not obliged to update this report for such changes. SSL has the right to make changes and modifications at any time. This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SSL or its affiliates to any registration or licensing requirement within such jurisdiction. Stockholding Services Limited (formerly known as SHCIL Services Limited)-(SSL) and its associate companies, their directors and their employees shall not be in any way responsible for any loss or damage that may arise to any recipient from any inadvertent error in the information contained in this report or any action taken on the basis of this information.

Disclosure

StockHolding Services Limited (formerly known as SHCIL Services Limited) -(SSL) is a SEBI Registered Research Analyst having registration no.: INH000001121. SSL is a SEBI Registered Corporate Stock broker having SEBI Single Registration No.: INZ000199936 and is a member of Bombay Stock Exchange (BSE)- Cash Segment and Derivatives Segment, National Stock Exchange (NSE)-Cash, derivatives and Currency Derivatives Segments and Multi Commodity Exchange of India (MCX) – Commodity Derivative. SSL has registered with SEBI to act as Portfolio Manager under the SEBI (Portfolio Managers) Regulations, 2020, bearing registration no. INP000007304 and also obtained registration as Depository Participant (DP) with CDSL and NSDL, SEBI Registration No.: IN-DP-471-2020. SSL is a wholly owned subsidiary of Stock Holding Corporation of India Limited (StockHolding). StockHolding is primarily engaged in the business of providing custodial services, designated depository participant (DDP) post trading services, Depositary Participant Services, Professional Clearing Services, Authorized Person services in association with SSL. Neither SSL nor its Research Analysts have been engaged in market making activity for the companies mentioned in the report /recommendation. SSL or their Research Analysts have not managed or co–managed public offering of securities for the subject company (ies) in the past twelve months.

Registrations granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. The Analysts engaged in preparation of this Report or his/her relative or SSL's associates: - (a) do not have any financial interests in the subject company mentioned in this Report; (b) do not own 1% or more of the equity securities of the subject company mentioned in the report as of the last day of the month preceding the publication of the research report; (c) do not have any material conflict of interest at the time of publication of the Report.

The Analysts engaged in preparation of this Report or his/her relatives or SSL's associates:- (a) have not received any compensation from the subject company in the past twelve months; (b) have not managed or co-managed public offering of securities for the subject company in the past twelve months; (c)have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (d) have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (e) has not received any compensation or other benefits from the subject company or third party in connection with the Report; (f) has not served as an officer, director or employee of the subject company; (g) is not engaged in market making activity for the subject company.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

"The securities quoted are for illustration only and are not recommendatory".

The investor is requested to take into consideration all the risk factors before actually trading in equity and derivative contracts. For grievances write to grievances@stockholdingservices.com. In case you require any clarification or have any query/concern, kindly write to us at ssl.research@stockholdingservices.com.

DEVARAJAN SADASIVAM
Digitally signed by DEVARAJAN SADASIVAM
Date: 2026.11.04 12:37:38 +05'30'

S. Devarajan
MBA (Finance & Foreign Trade), Ph.D. (Financial Management)
Head of Research & Quant Strategist

Sourabh Mishra
MMS (Finance)
Research Analyst

Mahesh R. Chavan
MSC (Finance)
Research Analyst

Kuldeep Malviya
MBA (Finance)
Research Analyst

Mahima Satish
BSC (Finance)
Research Associate